Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Changes of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides
Biochemistry. Biokhimiia;89(9):1643-1656
Early Generic Semaglutide in Canada-Implications for US Patients and Policy
JAMA internal medicine, 2026
Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations
Surgical endoscopy, 2026
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance
Nature metabolism, 2026
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
Nature medicine, 2026
Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data
Diabetes, obesity & metabolism, 2026
Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists
Diabetes, obesity & metabolism, 2026
Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Cohort Study
Endoscopy, 2026
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial
Lancet (London, England), 2026
Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study
The Lancet regional health. Europe, 2026;67:101738
GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) – beyond weight loss: a condensed scientific review
Drugs in context, 2026;15
Plant-Based Nutrition Alleviates Gastrointestinal Symptoms and Enhances Protein Intake during GLP-1 Therapy
Current developments in nutrition, 2026;10(7):109393
Weight Drop-Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-Mediated Weight Loss
Case reports in neurology, 2026;18(1):364-369
The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer’s Disease
Acta naturae;17(4):110-120
Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro
Metallomics : integrated biometal science;16(5)
Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis
Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
Annals of oncology : official journal of the European Society for Medical Oncology, 2026
Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025
Obesity (Silver Spring, Md.), 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
The lancet. Diabetes & endocrinology, 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
The lancet. Diabetes & endocrinology, 2026